Welcome to our dedicated page for Fulgent Genetics news (Ticker: FLGT), a resource for investors and traders seeking the latest updates and insights on Fulgent Genetics stock.
Fulgent Genetics, Inc. reports developments across a laboratory services business and a therapeutic development business. Its laboratory operations provide technical laboratory and genetic testing services, with professional interpretation of results by licensed physicians. Its therapeutic development work focuses on cancer drug candidates using a nanoencapsulation and targeted therapy platform designed for new and existing oncology drugs.
Recurring company news includes operating and financial results, revenue guidance, stock repurchase activity, laboratory-services partnerships, and precision medicine testing initiatives. Clinical updates also cover oncology programs such as FID-007 and FID-022, including disclosures related to head and neck cancer research and presentations at oncology meetings.
Fulgent Genetics (NASDAQ: FLGT) reported second quarter 2026 revenue of $85.4 million, up 20.1% sequentially and compared with $81.8 million a year ago. GAAP gross profit was $25.7 million for a 30.1% margin, and non-GAAP gross profit was $26.8 million, or 31.3%.
GAAP net loss attributable to Fulgent was $29.5 million, or $(1.05) per share, versus a $19.0 million loss in Q2 2025. Non-GAAP loss was $16.2 million, or $(0.58) per share, versus $2.1 million non-GAAP income a year earlier. Adjusted EBITDA loss was $17.1 million.
The company repurchased about 1.5 million shares in Q2 2026 for $23.8 million, part of 4.1 million shares repurchased year-to-date. Fulgent ended the quarter with $551.5 million in cash, cash equivalents, restricted cash and marketable securities and expects about $610 million by year-end 2026, assuming receipt of approximately $106.1 million in tax refunds.
For full year 2026, Fulgent now guides to revenue of $330–$340 million and a non-GAAP net loss of about $63–$67 million, or $(2.22)–$(2.35) per share. According to Fulgent, the guidance revision reflects processing delays affecting collection rates during the final phase of its revenue cycle management and billing transition.
Fulgent Genetics (NASDAQ:FLGT) will release its second quarter 2026 financial results after market close on Thursday, July 30, 2026. Management will host a conference call at 4:30 PM ET (1:30 PM PT), with a live audio webcast and replay available on the company’s investor relations website.
Fulgent (NASDAQ: FLGT) presented updated Phase 2 FID-007 data at ASCO 2026 in recurrent or metastatic head and neck squamous cell carcinoma after PD‑1 therapy. FID‑007 plus cetuximab showed 61.9% objective response rate, 6.7‑month median PFS, 7.4‑month median duration of response, and 63.4% one‑year overall survival, with a manageable safety profile and a Phase 3 study planned.
Fulgent (NASDAQ: FLGT) announced a rapid oral full abstract presentation at ASCO 2026 for Phase 2 trial FID-007 plus cetuximab in recurrent or metastatic head and neck squamous cell carcinoma.
Interim data in 42 patients showed 60% ORR, 7.2-month median PFS, and mainly grade 1–2 TRAEs, with some grade 3–4 events and one grade 5 pneumonia.
Foundation Medicine announced the launch of FoundationOne PGx, a pharmacogenetic test for oncology available in the United States through an expanded partnership with Fulgent Genetics (NASDAQ: FLGT) on May 4, 2026. The oncology-relevant panel covers genes tied to drug metabolism and actionable guidelines.
The panel includes CYP2C19, CYP2C9, CYP2D6, DPYD, G6PD, NUDT15, TPMT, UGT1A1 and UGT1A4 to inform dosing, anticipate toxicity, and reduce adverse drug reactions across chemotherapy, targeted therapies, and supportive care.
Fulgent Genetics (NASDAQ: FLGT) reported Q1 2026 results: revenue $71.1M, GAAP loss $24.8M ($(0.80)/share), Non‑GAAP loss $11.0M ( $(0.36)/share), and adjusted EBITDA loss $15.2M. The company repurchased ~2.6M shares for $40.1M in Q1 and ended the quarter with $604.7M in cash and equivalents (excluding an anticipated ~$106M tax refund). Full‑year 2026 revenue guidance is maintained at ~$350.0M; updated Non‑GAAP loss guidance is ~$46.0M or $(1.59)/share, and projected year‑end cash of ~$636.0M (assumptions apply).
Fulgent (NASDAQ: FLGT) announced its abstract on FID-007 plus cetuximab in recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) was selected for a Rapid Oral Abstract Session at ASCO 2026.
Presentation: Monday, June 1, 2026, 4:30–6:00pm CDT, hall D1, McCormick Place; Abstract #6020. The Phase 2 study (NCT06332092) evaluates dosing, pharmacokinetics, safety, and tolerability after PD-L1 inhibitor progression. The abstract posts on May 21, 2026; full slides will be on Fulgent investor relations at session start.
Fulgent (NASDAQ: FLGT) will release its first quarter 2026 financial results before the market opens on Friday, May 1, 2026. Management will host a conference call and live audio webcast at 8:30 AM ET (5:30 AM PT) the same day to discuss results and take questions. An audio replay will be available on the company Investor Relations website.
Fulgent Genetics (NASDAQ: FLGT) completed the acquisition of Bako Diagnostics and StrataDx on March 17, 2026. The company acquired certain assets of Bako and purchased StrataDx for a combined cash purchase price of approximately $56.9 million, subject to post-closing adjustments.
The acquisitions add a premier pathology laboratory and a premier dermatopathology laboratory to Fulgent's laboratory services businesses. Financial and legal advisors to both sides were disclosed.
Fulgent Genetics (NASDAQ: FLGT) reported Q4 2025 revenue of $83.3M (+9% YoY) and FY 2025 revenue of $322.7M (+14% YoY). GAAP loss for FY was $60.5M (loss of $1.97/share); non-GAAP income was $13.2M ($0.42/share). Cash and equivalents totaled $705.5M excluding an expected ~$106.3M tax refund. Management flagged a large customer moving volume in-house and provided 2026 guidance: revenue ~$350M, non-GAAP loss ~$(1.45) per share, and pro forma cash ~$685M, assuming a ~$56M acquisition spend for Bako and Strata Dx.